ERBB2 and inflammatory breast carcinoma: For the first time in this study, we reported that in HR−/HER2+ subtype breast cancer, the 3-year BCSS rate of IBC patients was higher than that of T4-non-IBC patients (89.5%% vs. 80.8%; log-rank p = 0.028) by analyzing different subgroups.